Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · CEL SCI CORP (CVM)

CEL-SCI signs Saudi Arabia Multikine distribution deal with Amarox, 50/50 revenue share

Neutral Impact 3 of 5 product/contract Written later

CEL-SCI entered a strategic partnership, distribution, and revenue sharing agreement with Amarox covering regulatory affairs, marketing, and potential commercialization of Multikine for head and neck cancer in Saudi Arabia. The companies will share net revenue from Saudi sales 50%/50%, but the filing gives no dollar amounts, and Multikine is not yet approved for sale in any market.

Key points

  • Agreement announced May 11, 2026; 8-K dated May 14, 2026
  • Net revenue from Multikine sales in Saudi Arabia to be shared 50%/50%, with the revenue share tied to receipt of Breakthrough Medicine Designation from the SFDA
  • Amarox to act as local regulatory representative and to become exclusive commercial distributor upon SFDA approval, with an optional extension to GCC countries

The filing

CompanyCEL SCI CORP (CVM)
Form8-K, current report
Filed with the SECMay 14, 2026, 5:16 PM ET
Accession number0001654954-26-004910

Items reported: 1.01 Material Definitive Agreement

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:51 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 14, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.